N+1 Singer downgraded shares of Consort Medical (LON:CSRT) to a hold rating in a research note published on Tuesday.

Separately, Stifel Nicolaus reissued a buy rating and set a GBX 1,250 ($16.82) price objective on shares of Consort Medical in a report on Thursday, November 9th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of GBX 1,188.17 ($15.99).

Shares of Consort Medical (LON:CSRT) traded up GBX 7 ($0.09) during mid-day trading on Tuesday, reaching GBX 1,144 ($15.40). 14,101 shares of the company traded hands, compared to its average volume of 22,318. Consort Medical has a 12 month low of GBX 960 ($12.92) and a 12 month high of GBX 1,180 ($15.88).

TRADEMARK VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/06/consort-medical-csrt-downgraded-by-n1-singer-to-hold.html.

About Consort Medical

Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.

Analyst Recommendations for Consort Medical (LON:CSRT)

Receive News & Stock Ratings for Consort Medical plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical plc and related stocks with our FREE daily email newsletter.